bioRxiv · 10.1101/843268
IRIS: Big data-informed discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing
Abstract
Aberrant alternative splicing (AS) is widespread in cancer, leading to an extensive but largely unexploited repertoire of potential immunotherapy targets. Here we describe IRIS, a computational platform leveraging large-scale cancer and normal transcriptomics data to discover AS-derived tumor antigens for T-cell receptor (TCR) and chimeric antigen receptor T-cell (CAR-T) therapies. Applying IRIS to RNA-Seq data from 22 glioblastomas resected from patients, we identified candidate epitopes and validated their recognition by patient T cells, demonstrating IRISs utility for expanding targeted cancer immunotherapy.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Pan, Y., Lee, A. H., Yang, H. T., Wang, Y., Xu, Y., Kadash-Edmondson, K. E., Phillips, J., Champhekar, A., Puig, C., Ribas, A., Witte, O. N., Prins, R. M., Xing, Y.. 2019-11-15. IRIS: Big data-informed discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. https://doi.org/10.1101/843268
Cite the original work for its findings. Save a collection to share your selection of sources.